EU Market Lead Theraclion's Sonovein is CE-marked and positioned as a non-invasive alternative to surgical varicose vein treatments, with no incisions and rapid recovery. Focus sales efforts on EU vascular clinics, phlebology centers, and ambulatory surgical centers where non-invasive options are valued. Leverage regulatory status and the competitive edge of being the only non-invasive option to drive partnerships with local distributors and hospital procurement teams.

US Entry Strategy In the United States, Sonovein is currently investigational and not available for sale. Sales opportunities exist through strategic alliances, licensing, or distribution partnerships as a pathway to regulatory clearance, pilots, or co-development with U.S. stakeholders. Target large U.S. vascular centers and payers once a clearance strategy is defined.

Hospital ROI Position Sonovein as a patient-friendly, operation-room-saving solution that can reduce procedure times and recovery delays. Build ROI case highlighting reduced OR utilization, scar-free outcomes, and quicker patient throughput to win hospital and payer support. Create materials for procurement conversations and integrated care pathways.

Clinical Evidence Invest in building clinical evidence and real-world outcomes to support reimbursement and wider adoption. Plan post-market studies, clinician training programs, and publish results showing safety, efficacy, and workflow efficiency to appeal to payers and hospital decision-makers.

Distribution Partners With a lean team, accelerate market reach through a dedicated channel partner network. Develop distributors and service partnerships in key EU and international markets, offer training, installation support, and joint marketing to scale access to Theraclion’s non-invasive solution.